In our GC cohort, we found that patients with high CDK1 and low CDK2 levels benefited from adjuvant chemotherapy (Log-rank test, p < 0.05; Fig. 4i), indicating that CDK1 and CDK2 levels could serve as biomarkers to gauge chemotherapeutic response in GC patients. This evidence concerns the gene CDK2 and gastric cancer.